← Leaderboards
Sharyn Katz
University Of Pennsylvania
$1,384,687
Attributed
$2,769,373
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $608.5K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,769,373 · 1
By mechanism
R01$2,769,373 · 1
Top collaborators
- Despina Kontos5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Robert H Vonderheide$28,425,019
- Christos Davatzikos$42,474,609
- Despina Kontos$13,752,487
- Rexford S Ahima$11,559,086
- Meenhard Herlyn$50,214,821
Others in their field
Other Emerging Leaders on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Leonard Freedman · Leidos Biomedical Research, Inc.$66,640,671
- Leonard Freedmand · Leidos Biomedical Research, Inc.$54,755,085
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$28,983,611
Research focus
ImmunotherapyInstitutionEffective TherapyImageImmunotherapeutic AgentCancer ImmunotherapyCancer PatientAmerican College Of Radiology Imaging NetworkCharacteristicsBiological MarkersClinical ManagementBlood VesselsClinical TranslationClinical TrialsCohortCytotoxic ChemotherapyDatabasesData SetDetectionDiagnosticCirculating DnaEarly TreatmentEastern Cooperative Oncology GroupMalignant Neoplasms
Grant awards (5)
Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC)on Immunotherapy$506,985
R01 · FY2025 · CA
Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC)on Immunotherapy$463,067
R01 · FY2024 · CA
Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC) on Immunotherapy$595,875
R01 · FY2023 · CA
Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC) on Immunotherapy$594,981
R01 · FY2022 · CA
Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC) on Immunotherapy$608,465
R01 · FY2021 · CA